ARVO 2024: Repeatability of FLIO and erythrocyte velocities in a nonhuman primate glaucoma model

News
Video

Osamah Saeedi, MD, MS, details his ARVO 2024 presentation and the study finding's implications on monitoring and treating glaucoma.

Osamah Saeedi, MD, MS, gives an overview of study results in his ARVO 2024 presentation, "Repeatability of Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) and Erythrocyte Velocities in a Nonhuman Primate Glaucoma Model," which found is that erythrocyte mediated angiography were highly repeatable.

Video Transcript

Editor’s note - The following transcript has been lightly edited for clarity.

Osamah Saeedi MD, MS:

I'm at ARVO 2024. Yesterday, I presented at the ARVO OVI conference, I presented a poster entitled, "The Repeatability and Reproducibility of Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) and Erythrocyte Mediated Angiography in a Non-human Primate Model." The key findings here are we adjusted intraocular pressure in a non-human, in an acute IOP elevation model, in a nonhuman primate. And what we found essentially that the fluorescence lifetime imaging ophthalmoscopy and erythrocyte mediated angiography were highly, erythrocyte mediated angiography were highly repeatable in this model. This is particularly important, because both of these modalities are going to give us further insight, potentially, into the metabolic and non-pressure related changes in glaucoma. So we wanted to make sure that they were not affected by intraocular pressure. While this work is early, it is important as glaucoma specialists that we look for biomarkers for the disease that are not related to intraocular pressure. Hence, knowing the metabolic activity of a tissue, knowing the retinal blood flow, may ultimately help us both monitor the disease early on in, the in the process, as well as develop new treatments that are not related to intraocular pressure. So we have now established that these measurements are highly repeatable in this model of glaucoma, and so we will now look at the long-term changes with elevated intraocular pressure chronically in this model.

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
© 2024 MJH Life Sciences

All rights reserved.